{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:53:24Z","timestamp":1787068404682,"version":"build-2736575974"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Forensic Sciences"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Among novel psychoactive substances, synthetic cannabinoid receptor agonists (SCRA) seem to have the widest diffusion in the population with no limitation to any particular demographic group. Information on drug consumption relies mostly on anonymized surveys and less on clinical or analytical data; notwithstanding, the huge efforts constantly made to enroll subjects to gather epidemiological data. In the present study, we collected 66 oral fluid samples from volunteers in a drug rehabilitation center in 2019 and early 2020. A liquid chromatography\u2013mass spectrometry method previously developed and validated by our Unit was applied to detect SCRA (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200910) in oral fluid. Results proved the presence of synthetic cannabinoids at a positivity rate of almost 20%, with detection frequency HU211(5\/13)\u2009&gt;\u2009UR144\/JWH122 (3\/13)\u2009&gt;\u2009JWH019\/JWH081\/AM2201 (1\/13). Concentrations were in the range\u2009&lt;\u2009LOQ \u22120.36\u2009ng\/ml. Synthetic cannabinoids consumption had not been declared by any volunteer. This study enabled for the unprecedent detection of synthetic cannabinoids use in the territory of Parma (Italy) in a high\u2010risk subpopulation. The identified SCRA proved the persistence into the market of the \u201cfirst\u2010generation\u201d JWH family into the Italian territory and the marketing of relatively new ones (AM\u20102201). Public health consequences represented by NPS consumption are still scarce; therefore, further studies are needed to understand the real diffusion in the population.\n                  <\/jats:p>","DOI":"10.1111\/1556-4029.15067","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:00:21Z","timestamp":1654066821000},"page":"1932-1937","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oral fluid analysis to monitor recent exposure to synthetic cannabinoids in a high\u2010risk subpopulation"],"prefix":"10.1111","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1363-3400","authenticated-orcid":false,"given":"Jennifer P.","family":"Pascali","sequence":"first","affiliation":[{"name":"Legal medicine and toxicology Department of Cardiologic, Thoracic and Vascular Sciences, University of Padova  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dagoli","sequence":"additional","affiliation":[{"name":"Legal Medicine, Department of Medicine and Surgery, University of Parma  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maina","family":"Antonioni","sequence":"additional","affiliation":[{"name":"Service for Pathological Dependencies (SerDp)  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Facetti","sequence":"additional","affiliation":[{"name":"Service for Pathological Dependencies (SerDp)  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Anzillotti","sequence":"additional","affiliation":[{"name":"Legal Medicine, Department of Medicine and Surgery, University of Parma  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cal\u00f2","sequence":"additional","affiliation":[{"name":"Legal Medicine, Department of Medicine and Surgery, University of Parma  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe\u00a0Fertonato","family":"Affini","sequence":"additional","affiliation":[{"name":"Service for Pathological Dependencies (SerDp)  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cantarelli","sequence":"additional","affiliation":[{"name":"Service for Pathological Dependencies (SerDp)  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8451-7212","authenticated-orcid":false,"given":"Rossana","family":"Cecchi","sequence":"additional","affiliation":[{"name":"Legal Medicine, Department of Medicine and Surgery, University of Parma  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"United Nations Office on Drugs and Crime (UNODC).Global smart update\u20132016.https:\/\/www.unodc.org\/documents\/scientific\/Global\u2010SMART\u2010Update\u20102016\u2010vol\u201016.pdf. Accessed 12 May 2022."},{"key":"e_1_2_7_3_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCCDA).European drug report 2021: Trends and developments 2021.https:\/\/www.emcdda.europa.eu\/publications\/edr\/trends\u2010developments\/2021_en. Accessed 27 Feb 2022."},{"key":"e_1_2_7_4_1","unstructured":"National Institute on Drug Abuse (NIDA).Monitoring the future 2020 survey results.https:\/\/nida.nih.gov\/drug\u2010topics\/trends\u2010statistics\/monitoring\u2010future. Accessed 12 May 2022."},{"issue":"2","key":"e_1_2_7_5_1","first-page":"103","article-title":"Metabolism and toxicological analysis of synthetic cannabinoids in biological fluids and tissues","volume":"28","author":"Presley BC","year":"2016","journal-title":"Forensic Sci Rev"},{"key":"e_1_2_7_6_1","unstructured":"Centers for Disease Control and Prevention.Synthetic cannabinoids: An overview for healthcare providers.2018.https:\/\/www.cdc.gov\/nceh\/hsb\/chemicals\/sc\/healthcare.html. Accessed 17 Feb 2022."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13060"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkaa089"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.705643"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010020\u201002926\u20109"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389201018666171122113934"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkx020"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2345"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxac.2016.12.004"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X15666170828162057"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2019.02.029"},{"key":"e_1_2_7_17_1","unstructured":"Department of Health and Human Services Substance Abuse and Mental Health Services Administration.Mandatory guidelines for federal workplace drug testing programs.2008.http:\/\/www.gpo.gov\/fdsys\/pkg\/FR\u20102008\u201011\u201025\/pdf\/E8\u201026726.pdf. Accessed 24 Feb 2022."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.284"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkab114"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102015\u20100027"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2019.04.029"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/jdrugpo.2018.03.013"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2310"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2019.109941"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00439"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku040"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010013\u20106887\u20100"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108962"},{"key":"e_1_2_7_29_1","unstructured":"European monitoring Centre for Drugs and Drug Addiction (EMCDDA).Synthetic cannabinoids in Europe 2017.https:\/\/www.emcdda.europa.eu\/topics\/pods\/synthetic\u2010cannabinoids_en. Accessed 13 May 2022."},{"key":"e_1_2_7_30_1","volume-title":"European drug report 2018: Trends and developments","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2018"},{"key":"e_1_2_7_31_1","volume-title":"European drug report 2019: Trends and developments","author":"European Monitoring Centre for Drugs and Drug Addiction EMCDDA)","year":"2019"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249414"}],"container-title":["Journal of Forensic Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1556-4029.15067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1556-4029.15067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1556-4029.15067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T22:02:33Z","timestamp":1692741753000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1556-4029.15067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/1556-4029.15067"],"URL":"https:\/\/doi.org\/10.1111\/1556-4029.15067","archive":["Portico"],"relation":{},"ISSN":["0022-1198","1556-4029"],"issn-type":[{"value":"0022-1198","type":"print"},{"value":"1556-4029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2022-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}